Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Value in Health

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jval.2011.08.1737PMID 22264973
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer

  2012cited by this paper
• Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: An economic evaluation

  2010cited by this paper
• Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.

  2010cited by this paper
• Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer

  2010cited by this paper
• Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer

  2010cited by this paper
• Best supportive care in lung cancer trials is inadequately described: a systematic review.

  2010cited by this paper
• Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.

  2009cited by this paper
• Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systematic review.

  2009cited by this paper
• Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.

  2009cited by this paper
• Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.

  2009cited by this paper
• The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.

  2009cited by this paper
• Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.

  2009cited by this paper
• Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

  2009cited by this paper
• How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.

  2009cited by this paper
• Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.

  2009cited by this paper
• Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

  2008cited by this paper
• Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies.

  2007cited by this paper
• Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer

  2007cited by this paper
• Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.

  2007cited by this paper
• The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.

  2007cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

  2005cited by this paper
• Optimizing first-line treatment options for patients with advanced NSCLC.

  2005cited by this paper
• Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  2004cited by this paper
• American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

  2004cited by this paper
• Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review).

  2004cited by this paper
• Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

  2004cited by this paper
• Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

  2003cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Willingness to Pay for a Quality-adjusted Life Year

  2000cited by this paper
• LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.

  1997cited by this paper
• The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer.

  1996cited by this paper

• Cost-effectiveness models of non-small cell lung cancer: A systematic literature review.

  2025cites this paper
• Cost-Utility Analysis of Maintenance Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care Alone in Treating Patients With Non-Small Cell Lung Cancer in Jordan.

  2024cites this paper
• Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC

  2020cites this paper
• Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer

  2019cites this paper
• Health Technology Assessment Challenges in Oncology: 20 Years of Value in Health.

  2019cites this paper
• A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).

  2018cites this paper
• Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study.

  2018cites this paper
• Intégration des mesures intermédiaires de survie dans les évaluations économiques en cancer du sein métastatique

  2017cites this paper
• Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.

  2017cites this paper
• A Cost‐Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD‐L1 Testing

  2016cites this paper
• Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)

  2016cites this paper
• Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2016cites this paper
• A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PD-L1 testing

  2016cites this paper
• Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer

  2015cites this paper
• Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C

  2015cites this paper
• Maintenance therapy in non-small cell lung cancer

  2015cites this paper
• Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications

  2014cites this paper
• Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model Analysis

  2014cites this paper
• Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.

  2013cites this paper
• Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis

  2013cites this paper
• Aspects médico-économiques de la prise en charge des cancers du poumon non à petites cellules : maintenir la qualité de la prise en charge dans un cadre économique contraint

  2013cites this paper
• Treatment patterns and healthcare costs among patients with advanced non-small-cell lung cancer

  2013cites this paper
• Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.

  2013cites this paper
• Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland

  2013cites this paper
• Advanced Non-Small Cell Lung Cancer (NSCLC): Maintenance Therapy for All?

  2012cites this paper
• Preliminary Economic Evaluation of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: An "Early Look" Model Based on Phase II Results

  2012cites this paper
• Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

  2012cites this paper
• Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

  2012cites this paper
• Impact médico-économique du cancer du poumon

  2012cites this paper
• Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic’s View

  2012cites this paper
• Clinicoeconomics and Outcomes Research Dovepress Economic Evaluation of First-line and Maintenance Treatments for Advanced Non-small Cell Lung Cancer: a Systematic Review

  year unknowncites this paper